Inhibitor Therapeutics Provides Clinical Development Update
Inhibitor Therapeutics, Inc. (OTCQB: INTI) is making significant progress in advancing its itraconazole formulation, which is designed to treat Basal Cell Carcinomas. This is particularly important for patients diagnosed with Basal Cell Carcinoma Nevus Syndrome, commonly referred to as Gorlin Syndrome. The company is working closely with The Gorlin Syndrome Alliance and has consulted its experienced Scientific Advisory Board to ensure a fast track toward approval from the U.S. Food and Drug Administration (FDA).
Regulatory Guidance and Milestones
Inhibitor has submitted a Pre-Investigational New Drug (PIND) application that has caught the attention of the FDA’s Division of Dermatology and Dentistry, as well as insights from the Division of Oncology 3 when necessary. The preliminary feedback from the FDA has been positive, which is helping Inhibitor prepare for an Investigational New Drug Application (IND).
Engagement with Avior Bio
To develop a new proprietary and potentially patentable itraconazole formulation, Inhibitor has chosen to collaborate with Avior Bio. This partnership aims to connect the new formulation with the one used in previous clinical studies, as well as the generic itraconazole formulation, by conducting a pharmacokinetic (PK) study. Importantly, itraconazole is known for its well-established safety profile, and previous research has demonstrated its significant efficacy against Basal Cell Carcinomas in patients with Gorlin Syndrome.
Clinical Study Outcomes
The recent clinical study focused on 477 targeted tumors and yielded impressive results: 399 tumors showed some level of size reduction, with 275 tumors (57.7%) achieving a clinically significant reduction of 30% or more. Furthermore, 130 tumors (27.3%) completely resolved, underscoring the treatment's potential effectiveness.
Future Development Plans
Inhibitor’s ongoing development strategy for its itraconazole formulation includes several essential goals. These involve finalizing the new proprietary formulation and seeking patent protection, conducting and analyzing results from the bridging PK study, and preparing to submit the IND to the FDA. The company expects to be ready for this IND submission by the end of the first quarter of the upcoming year.
Company Commitment and Contact Information
Inhibitor Therapeutics is committed to enhancing patient outcomes through innovative therapies. For more information about the company's mission and products, interested individuals can visit their website. If there are specific questions, they are encouraged to reach out via the contact page for assistance from the company's representatives.
Frequently Asked Questions
What is the focus of Inhibitor Therapeutics, Inc.?
Inhibitor Therapeutics is dedicated to developing treatments for Basal Cell Carcinomas, especially for patients with Gorlin Syndrome.
What is the status of Inhibitor's itraconazole formulation?
The itraconazole formulation is progressing toward IND submission, with preliminary feedback from the FDA aiding in this process.
Who is Avior Bio?
Avior Bio is the partner selected by Inhibitor Therapeutics to assist in developing a new patentable itraconazole formulation.
What were the results of the recent clinical study?
The clinical study indicated that 57.7% of the targeted tumors experienced a significant reduction in size, while 27.3% completely resolved.
How can I learn more about Inhibitor Therapeutics?
To find out more, individuals can visit Inhibitor's website or contact their team directly through the contact page.
